General Information of Drug (ID: DM3427C)

Drug Name
PF-4427429 Drug Info
Synonyms PF-04427429; RI-307; Anti-CGRP antibodies (migraine), Pfizer
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM3427C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eptinezumab DM5LJCI Migraine 8A80 Approved [3]
TEV-48125 DMMTKC6 Migraine 8A80 Phase 3 [4]
ALD-403 DM6RBYT Migraine 8A80 Phase 2 [5]
CGRP DMCRPKS Asthma CA23 Discontinued in Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin gene-related peptide (CALC) TTAFORY NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT01117233) Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429. U.S. National Institutes of Health.
2 Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30.